Quidel Corporation  

(Public, NASDAQ:QDEL)   Watch this stock  
Find more results for disease
21.81
-0.21 (-0.95%)
Real-time:   11:47AM EST
NASDAQ real-time data - Disclaimer
Currency in USD
Range 21.69 - 22.06
52 week 13.21 - 23.94
Open 22.06
Vol / Avg. 6,219.00/120,687.00
Mkt cap 721.13M
P/E     -
Div/yield     -
EPS -0.38
Shares 32.64M
Beta 1.24
Inst. own 94%
Feb 15, 2017
Q4 2016 Quidel Corp Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Nov 29, 2016
Quidel Corp at Piper Jaffray Healthcare Conference - Webcast
Oct 26, 2016
Q3 2016 Quidel Corp Earnings Call - Webcast
Oct 26, 2016
Q3 2016 Quidel Corp Earnings Release
Sep 7, 2016
Quidel Corp at Wells Fargo Securities Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin -1.16% -3.10%
Operating margin 4.31% 1.40%
EBITD margin - 13.32%
Return on average assets -0.61% -1.42%
Return on average equity -1.18% -2.62%
Employees 624 -
CDP Score - -

Address

12544 High Bluff Dr Ste 200
SAN DIEGO, CA 92130-3050
United States - Map
+1-858-5521100 (Phone)
+1-858-4534338 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Quidel Corporation is engaged in the development, manufacturing and marketing of diagnostic testing solutions. The Company's diagnostic testing solutions primarily include applications in infectious diseases, women's health and gastrointestinal diseases. It sells its products directly to end users and distributors, in each case, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail clinics and wellness screening centers. It markets its products in the United States through a network of national and regional distributors and a direct sales force. Internationally, it sells and markets primarily through distributor arrangements. Its diagnostic solutions are used in the detection and diagnosis of many critical diseases and other medical conditions, including autoimmune diseases, bone health and thyroid diseases. It provides diagnostic testing solutions under various brand names, including Quidel, QuickVue+ and Thyretain.

Officers and directors

Kenneth F. Buechler Ph.D. Chairman of the Board
Age: 61
Bio & Compensation  - Reuters
Douglas C. Bryant President, Chief Executive Officer, Director
Age: 58
Bio & Compensation  - Reuters
Randall J. Steward Chief Financial Officer
Age: 61
Bio & Compensation  - Reuters
Robert Joseph Bujarski J.D. Senior Vice President - Business Development, General Counsel and Corporate Secretary
Age: 47
Bio & Compensation  - Reuters
Michael D. Abney Jr. Senior Vice President - Distribution
Age: 52
Bio & Compensation  - Reuters
Werner Kroll Ph.D Senior Vice President,R&D
Age: 59
Bio & Compensation  - Reuters
Edward Keith Russell Senior Vice President - Global Commercial Operations
Age: 48
Bio & Compensation  - Reuters
John D. Tamerius Ph.D. Senior Vice President - Strategic and External Affairs
Age: 70
Bio & Compensation  - Reuters
Charles P. Slacik CPA Director
Age: 61
Bio & Compensation  - Reuters
Thomas D. Brown Independent Director
Age: 67
Bio & Compensation  - Reuters